[HTML][HTML] Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: a focus on aducanumab and lecanemab
M Shi, F Chu, F Zhu, J Zhu - Frontiers in aging neuroscience, 2022 - frontiersin.org
Alzheimer's disease (AD) is the most prevalent form of age-related dementia in the world,
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …
Aβ-oligomers: A potential therapeutic target for Alzheimer's disease
The cascade of amyloid formation relates to multiple complex events at the molecular level.
Previous research has established amyloid plaque deposition as the leading cause of …
Previous research has established amyloid plaque deposition as the leading cause of …
[HTML][HTML] Trial of solanezumab in preclinical Alzheimer's disease
RA Sperling, MC Donohue, R Raman… - … England Journal of …, 2023 - Mass Medical Soc
Background Trials of monoclonal antibodies that target various forms of amyloid at different
stages of Alzheimer's disease have had mixed results. Methods We tested solanezumab …
stages of Alzheimer's disease have had mixed results. Methods We tested solanezumab …
[HTML][HTML] Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
SF Ackley, SC Zimmerman, WD Brenowitz… - Bmj, 2021 - bmj.com
Objective To evaluate trials of drugs that target amyloid to determine whether reductions in
amyloid levels are likely to improve cognition. Design Instrumental variable meta-analysis …
amyloid levels are likely to improve cognition. Design Instrumental variable meta-analysis …
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
PL McGeer, EG McGeer - Acta neuropathologica, 2013 - Springer
The amyloid cascade hypothesis is widely accepted as the centerpiece of Alzheimer
disease (AD) pathogenesis. It proposes that abnormal production of beta amyloid protein …
disease (AD) pathogenesis. It proposes that abnormal production of beta amyloid protein …
[HTML][HTML] Circulating miRNA biomarkers for Alzheimer's disease
P Kumar, Z Dezso, C MacKenzie, J Oestreicher… - PloS one, 2013 - journals.plos.org
A minimally invasive diagnostic assay for early detection of Alzheimer's disease (AD) is
required to select optimal patient groups in clinical trials, monitor disease progression and …
required to select optimal patient groups in clinical trials, monitor disease progression and …
[HTML][HTML] A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
E Karran, J Hardy - Annals of neurology, 2014 - ncbi.nlm.nih.gov
In 1906, Alois Alzheimer described the neuropathology of the disease that was to bear his
name. 1 Subsequently, our understanding of Alzheimer disease (AD) has grown …
name. 1 Subsequently, our understanding of Alzheimer disease (AD) has grown …
Terminally modified RNA
T Chakraborty, S Bancel, SG Hoge, A Roy… - US Patent …, 2017 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Modified polynucleotides for the production of biologics and proteins associated with human disease
S Bancel, T Chakraborty, A De Fougerolles… - US Patent …, 2015 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Modified polynucleotides for the production of secreted proteins
T Chakraborty, A De Fougerolles - US Patent 9,192,651, 2015 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …